Literature DB >> 10806813

Extrahepatic and intrahepatic replication and expression of hepatitis C virus.

D Tian1, D Yang, W Wang, Q Xia, S Shi, P Song, L Theilmann.   

Abstract

In order to determine the replication sites of hepatitis C virus, the in situ hybridization and immunohistochemical technique using digoxin-labeled 531 bp plus-strand and minus-strand HCVRNA probes were employed to detect HCVRNA in the liver tissues, bone marrow mononuclear cells and peripheral blood mononuclear cells (PBMCs) from the patients with chronic hepatitis C, and in HCV transfected COS cells. The results showed that both plus-strand and minus-strand HCVRNA were detected in 80% of liver tissues (4/5). Plus-strand HCVRNA could be detected in 90% of PBMCs and bone marrow mononuclear cells (18/20), minus-strand HCVRNA in 25% of PBMCs. In HCV transfected COS cells, plus-strand HCVRNA distributed evenly in 20% cellular nuclei and cytoplasms. No minus-strand HCVRNA was detected in the bone marrow mononuclear cells and HCV transfected COS cells. The positive signal appeared in more cells when the liver tissues, PBMCs and marrow mononuclear cells were hybridized by plus-strand probes than when hybridized by minus-strand probes. Our results suggested that the hepatocytic cytoplasms and PBMC cytoplasms were the replication sites of HCV, but the marrow mononuclear cells were not the replication sites of HCV although they were infected by HCV. HCV infection might be accounted for the pathogenesis of chronic hepatitis and relapse of hepatitis C after liver transplantation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10806813     DOI: 10.1007/bf02888524

Source DB:  PubMed          Journal:  J Tongji Med Univ        ISSN: 0257-716X


  8 in total

1.  Hepatitis C virus propagates in salivary glands.

Authors:  K Takamatsu; I Okayasu; Y Koyanagi; N Yamamoto
Journal:  J Infect Dis       Date:  1992-05       Impact factor: 5.226

Review 2.  Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease.

Authors:  M Houghton; A Weiner; J Han; G Kuo; Q L Choo
Journal:  Hepatology       Date:  1991-08       Impact factor: 17.425

3.  [Recurrent and acquired hepatitis C virus infection in patients after liver transplantation].

Authors:  L Theilmann; T Goeser
Journal:  Z Gastroenterol       Date:  1993-02       Impact factor: 2.000

4.  Detection of hepatitis C virus RNA in the liver by in situ hybridization.

Authors:  Y Tanaka; N Enomoto; S Kojima; L Tang; M Goto; F Marumo; C Sato
Journal:  Liver       Date:  1993-08

5.  Correlation of plasma hepatitis C virus RNA levels with serum alanine aminotransferase in non-A, non-B chronic liver disease.

Authors:  M Kurosaki; N Enomoto; C Sato; N Sakamoto; Y Hoshino; H Haritani; F Marumo
Journal:  J Med Virol       Date:  1993-03       Impact factor: 2.327

6.  Detection of hepatitis C virus (HCV) RNA sequences in liver tissue by in situ hybridization.

Authors:  E Lamas; P Baccarini; C Housset; D Kremsdorf; C Bréchot
Journal:  J Hepatol       Date:  1992-09       Impact factor: 25.083

7.  Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

Authors:  J Y Lau; G L Davis; J Kniffen; K P Qian; M S Urdea; C S Chan; M Mizokami; P D Neuwald; J C Wilber
Journal:  Lancet       Date:  1993-06-12       Impact factor: 79.321

8.  Peripheral blood leukocytes serve as a possible extrahepatic site for hepatitis C virus replication.

Authors:  H M Müller; E Pfaff; T Goeser; B Kallinowski; C Solbach; L Theilmann
Journal:  J Gen Virol       Date:  1993-04       Impact factor: 3.891

  8 in total
  2 in total

1.  Hepatitis C virus infection of human hepatoma cell line 7721 in vitro.

Authors:  Z Q Song; F Hao; F Min; Q Y Ma; G D Liu
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

Review 2.  Human cell types important for hepatitis C virus replication in vivo and in vitro: old assertions and current evidence.

Authors:  Dennis Revie; Syed Zaki Salahuddin
Journal:  Virol J       Date:  2011-07-11       Impact factor: 4.099

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.